IL195152A - Compounds for use in treating diseases of cell culture - Google Patents

Compounds for use in treating diseases of cell culture

Info

Publication number
IL195152A
IL195152A IL195152A IL19515208A IL195152A IL 195152 A IL195152 A IL 195152A IL 195152 A IL195152 A IL 195152A IL 19515208 A IL19515208 A IL 19515208A IL 195152 A IL195152 A IL 195152A
Authority
IL
Israel
Prior art keywords
compounds
treatment
cell proliferative
proliferative disorders
disorders
Prior art date
Application number
IL195152A
Other languages
English (en)
Hebrew (he)
Other versions
IL195152A0 (en
Inventor
Eliahu Kaplan
Original Assignee
New Era Biotech Ltd
Eliahu Kaplan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Era Biotech Ltd, Eliahu Kaplan filed Critical New Era Biotech Ltd
Publication of IL195152A0 publication Critical patent/IL195152A0/en
Publication of IL195152A publication Critical patent/IL195152A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL195152A 2006-05-09 2008-11-06 Compounds for use in treating diseases of cell culture IL195152A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79910306P 2006-05-09 2006-05-09
PCT/IB2007/002471 WO2007129226A2 (en) 2006-05-09 2007-05-09 Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders

Publications (2)

Publication Number Publication Date
IL195152A0 IL195152A0 (en) 2009-09-22
IL195152A true IL195152A (en) 2015-10-29

Family

ID=38668152

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195152A IL195152A (en) 2006-05-09 2008-11-06 Compounds for use in treating diseases of cell culture

Country Status (12)

Country Link
US (3) US20090306214A1 (enExample)
EP (1) EP2026775B1 (enExample)
JP (1) JP5225264B2 (enExample)
AU (1) AU2007246779B2 (enExample)
CA (1) CA2651375C (enExample)
DK (1) DK2026775T3 (enExample)
ES (1) ES2542344T3 (enExample)
HU (1) HUE026820T2 (enExample)
IL (1) IL195152A (enExample)
PL (1) PL2026775T3 (enExample)
PT (1) PT2026775E (enExample)
WO (1) WO2007129226A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642290B2 (en) * 2002-10-03 2010-01-05 Novaremed Limited Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
US7674829B2 (en) * 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases
GB0804213D0 (en) * 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
US8802734B2 (en) * 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
WO2011030205A1 (en) * 2009-09-09 2011-03-17 Novaremed Ltd. N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
KR20160013204A (ko) 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4185279A4 (en) 2020-07-24 2024-05-01 Secura Bio, Inc. TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1908322A (en) * 1932-04-07 1933-05-09 Claude R Cook Weed puller
US2908691A (en) * 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7642290B2 (en) * 2002-10-03 2010-01-05 Novaremed Limited Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
US7674829B2 (en) * 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases

Also Published As

Publication number Publication date
AU2007246779B2 (en) 2013-11-28
CA2651375A1 (en) 2007-11-15
WO2007129226A2 (en) 2007-11-15
US20120108666A1 (en) 2012-05-03
US20140039060A1 (en) 2014-02-06
WO2007129226A3 (en) 2008-05-08
EP2026775B1 (en) 2015-04-29
ES2542344T3 (es) 2015-08-04
HUE026820T2 (en) 2016-07-28
DK2026775T3 (en) 2015-06-29
US20090306214A1 (en) 2009-12-10
JP5225264B2 (ja) 2013-07-03
AU2007246779A1 (en) 2007-11-15
EP2026775A2 (en) 2009-02-25
IL195152A0 (en) 2009-09-22
JP2009536191A (ja) 2009-10-08
PL2026775T3 (pl) 2015-12-31
PT2026775E (pt) 2015-08-05
CA2651375C (en) 2015-12-22

Similar Documents

Publication Publication Date Title
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
EP2178370A4 (en) COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISEASES
ZA200906210B (en) 3-Imidazolyl-Indoles for the treatment of proliferative diseases
IL196998A0 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
IL185016A0 (en) Compounds for the treatment of proliferative disorders
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
PL1975226T3 (pl) Płynna kompozycja do obróbki
IL205939A (en) Compounds for use in the treatment of lysosomal disorders
EP1853539A4 (en) HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES
PT1978947E (pt) Derivados nitro-óxido para utilização no tratamento de distrofias musculares
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
IL195152A0 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
PL2358697T3 (pl) Związki izoindolinowe do zastosowania w leczeniu raka
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
AU2008233088A8 (en) Calcimimetic compounds for use in the treatment of bowel disorders
IL207965A (en) Compounds to treat or prevent pain
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
GB0714447D0 (en) Cannabidiol for use in the treatment of neurodegenerative conditions
PT2481407T (pt) Compostos para utilização no tratamento de distúrbios cognitivos
IL199214A0 (en) New combination for use in the treatment of inflammatory disorders
GB0822486D0 (en) Compounds for use in the treatment of pain
ZA200901015B (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
IL206189A (en) Compounds for use in cancer treatment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed